Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
| Revenue (TTM) | $38.90B |
| Gross Profit (TTM) | $28.19B |
| EBITDA | $17.63B |
| Operating Margin | 35.80% |
| Return on Equity | 78.30% |
| Return on Assets | 8.91% |
| Revenue/Share (TTM) | $72.11 |
| Book Value | $26.53 |
| Price-to-Book | 17.35 |
| Price-to-Sales (TTM) | 6.40 |
| EV/Revenue | 7.45 |
| EV/EBITDA | 15.95 |
| Quarterly Earnings Growth (YoY) | 19.40% |
| Quarterly Revenue Growth (YoY) | 8.50% |
| Shares Outstanding | $540.91M |
| Float | $539.43M |
| % Insiders | 0.23% |
| % Institutions | 84.99% |
Volatility is currently expanding
Amgen produces strong revenue growth and healthy margins by focusing on complex biological therapies and rare diseases. Pfizer maintains a massive global reach and offers a more conservative balance sheet with a lower valuation profile.
Findings Represent Largest and Most Rigorous Head-to-Head Real-World Outcomes Analysis of Repatha and Ezetimibe Study Examined More Than Half a Million Adults Living with Heart Disease Results Provide Important New Clinical Evidence to Inform Non-Statin Treatment Decisions for Patients THOUSAND OAKS, Calif., Nov. 5, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced results from a large real-world study showing that treatment with Repatha® (evolocumab) reduced the risk of fatal or nonfatal heart attacks by 20% compared with ezetimibe in people with atherosclerotic cardiovascular disease (ASCVD) and prior statin use.
Amgen raises its 2026 outlook after Q3 earnings and revenue beat estimates, as IMDELLTRA advances and MariTide offers potential long-term growth opportunities.
Amgen shares fall despite Q3 earnings and revenue beats. Steep declines in Prolia and Xgeva offset strong growth across key drug portfolios and raised 2026 guidance.
Amgen Inc. (AMGN) Q3 2026 Earnings Call Transcript
THOUSAND OAKS, Calif., Nov. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2026.
AMGN, PFE, MRNA, NVO and VTRS are set to report this week as recent beats and key drug demand set up a pivotal Q3 earnings test for pharma giants.
Amgen's cancer drug Imdelltra has been shown to be effective in treating advanced lung cancer when paired with AstraZeneca's Imfinzi. The risk of death was cut by 58% for patients who used the combination treatment.
Beyond analysts' top-and-bottom-line estimates for Amgen (AMGN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.
Amgen (NASDAQ:AMGN | AMGN Price Prediction) is expected to report third-quarter results on Tuesday, November 3, after the close. The stock is up 41.28% year to date, and management has already warned that spending will jump.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AMGN and any ticker you trade — then tracks every position and per-strategy win rate.
